KIR3DL1 and metastatic colorectal cancer: De Re et al.[34] have reported that the presence of activating telomeric KIR receptors in the absence of KIR2DS4 and KIR3DL1 might increase the likelihood of complete response to chemotherapy in metastatic colorectal cancer patients.